Johannes Schetelig, MD, MSc, discusses the sequencing of allogeneic stem cell transplant to achieve the best response in patients with acute myeloid leukemia/
Johannes Schetelig, MD, MSc, discusses the sequencing of allogeneic stem cell transplant to achieve the best response in patients with acute myeloid leukemia (AML). Schetelig participated in a debate on this subject at the SOHO 2023 Annual Meeting.
Transcript:
0:07 | It used to be an accepted standard of care to offer salvage chemotherapy with a goal to achieve a remission protocol transplantation. This standard of care is, I would say, challenged by the data which we present because we show, which is that it doesn't deliver any benefit to the patient. But so far, it is a standard, which at the same time is a standard nobody likes because we do know that, at maximum, 50% of the patients benefit in terms of achieving a [complete response], which is what we want to achieve.
0:52 | In other words, 50% of the patients don't achieve what we want to achieve with a salvage chemotherapy they just have side effects. So, it is an undesired standard. And this standard has been challenged by the data from the ASAP trial. And especially even those patients were who have achieved a complete response after salvage chemotherapy, we don't see an indication in the data that they benefit from having achieved this car it essentially is just a kind of biomarker if you use chemotherapy and demonstrate that the disease is chemotherapy sensitive, then you know that this is a better risk disease than disease which is not chemo sensitive. So, offering chemotherapy just gives us information on the disease risk of this very disease.
FDA Approves Remestemcel-L in Pediatric Patients With Acute GVHD
December 18th 2024Following a complete response letter and biologics license application resubmission, the FDA has approved remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More